Ping Du1, Sarah Brendle2, Janice Milici3, Fabian Camacho4, John Zurlo5, Neil Christensen2, Craig Meyers3. 1. Department of Medicine, The Pennsylvania State University College of Medicine, USA ; Department of Public Health Sciences, The Pennsylvania State University College of Medicine, USA. 2. Department of Pathology, The Pennsylvania State University College of Medicine, USA. 3. Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, USA. 4. Department of Public Health Sciences, The Pennsylvania State University College of Medicine, USA. 5. Department of Medicine, The Pennsylvania State University College of Medicine, USA.
Abstract
OBJECTIVE: Human papillomavirus (HPV)-associated cancers are important public health problems in HIV-infected people. Assays based on HPV virus-like particles (VLP) and pseudoviruses (PsV) are commonly used to examine HPV antibody responses in HIV-infected people, but neutralization assays with native HPV have not been utilized and a comparison of these three assays is lacking. We evaluated the agreement of assays using VLP, native HPV and PsV in detecting HPV16 and 18 antibodies in HIV-infected women. METHODS: The VLP-based ELISA (VLP-ELISA) was used to detect antibody responses to HPV16 and 18 and cottontail rabbit papillomavirus (CRPV) VLP antigens. Neutralization assays with native HPV (NA-HPV) and with PsV (NA-PsV) were conducted to examine HPV16 or 18 neutralizing antibodies. Intra class correlation coefficients (ICC) and kappa coefficients were used to assess the agreements of seropositivity between the assays. RESULTS: The seroprevalence detected by the VLP-ELISA, NA-HPV and NA-PsV in 94 HIV-infected women was 35%, 51% and 27% for HPV16 and 14%, 44% and 21% for HPV18. Cross-reactivity between HPV16 and HPV18 was 0.35, 0.04 and 0.33 (kappa coefficients) for the VLP-ELISA, NA-HPV and NA-PsV. The agreements of seropositivity between the three assays were low. Six women who were HPV16 DNA positive were seropositive by the NA-HPV but only two were HPV16 seropositive by the VLP-ELISA or NA-PsV. One HPV18 DNA positive woman was seropositive by all three assays. Repeated tests indicated excellent reproducibility of the NA-HPV. CONCLUSION: HPV serology results vary across different assays. The NA-HPV appears to be a sensitive and reliable approach in detecting natural HPV antibodies in HIV-infected women. The NA-HPV can be applied in both HPV natural history studies and vaccine studies in HIV-infected people.
OBJECTIVE:Human papillomavirus (HPV)-associated cancers are important public health problems in HIV-infected people. Assays based on HPV virus-like particles (VLP) and pseudoviruses (PsV) are commonly used to examine HPV antibody responses in HIV-infected people, but neutralization assays with native HPV have not been utilized and a comparison of these three assays is lacking. We evaluated the agreement of assays using VLP, native HPV and PsV in detecting HPV16 and 18 antibodies in HIV-infectedwomen. METHODS: The VLP-based ELISA (VLP-ELISA) was used to detect antibody responses to HPV16 and 18 and cottontail rabbit papillomavirus (CRPV) VLP antigens. Neutralization assays with native HPV (NA-HPV) and with PsV (NA-PsV) were conducted to examine HPV16 or 18 neutralizing antibodies. Intra class correlation coefficients (ICC) and kappa coefficients were used to assess the agreements of seropositivity between the assays. RESULTS: The seroprevalence detected by the VLP-ELISA, NA-HPV and NA-PsV in 94 HIV-infectedwomen was 35%, 51% and 27% for HPV16 and 14%, 44% and 21% for HPV18. Cross-reactivity between HPV16 and HPV18 was 0.35, 0.04 and 0.33 (kappa coefficients) for the VLP-ELISA, NA-HPV and NA-PsV. The agreements of seropositivity between the three assays were low. Six women who were HPV16 DNA positive were seropositive by the NA-HPV but only two were HPV16 seropositive by the VLP-ELISA or NA-PsV. One HPV18 DNA positive woman was seropositive by all three assays. Repeated tests indicated excellent reproducibility of the NA-HPV. CONCLUSION:HPV serology results vary across different assays. The NA-HPV appears to be a sensitive and reliable approach in detecting natural HPV antibodies in HIV-infectedwomen. The NA-HPV can be applied in both HPV natural history studies and vaccine studies in HIV-infected people.
Authors: Nicolas Wentzensen; Ana Cecilia Rodriguez; Raphael Viscidi; Rolando Herrero; Allan Hildesheim; Arpita Ghosh; Jorge Morales; Sholom Wacholder; Diego Guillen; Mario Alfaro; Mahboobeh Safaeian; Robert D Burk; Mark Schiffman Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: A Petter; K Heim; M Guger; A Ciresa-Kö Nig; N Christensen; M Sarcletti; U Wieland; H Pfister; R Zangerle; R Höpfl Journal: J Gen Virol Date: 2000-03 Impact factor: 3.891
Authors: Mel Krajden; Darrel Cook; Amanda Yu; Ron Chow; Wendy Mei; Shelly McNeil; Deborah Money; Marc Dionne; Karuna P Karunakaran; Joel M Palefsky; Simon Dobson; Gina Ogilvie; Martin Petric Journal: Clin Vaccine Immunol Date: 2011-01-19
Authors: Sarah A Brendle; Jingwei Li; Nancy M Cladel; Karla K Balogh; Jennifer Booth; Debra A Shearer; Vonn Walter; Song Lu; Neil D Christensen; Danielle Covington; Jake DeBroff; Janice Milici; Yusheng Zhu; Raphael Viscidi; Jiafen Hu Journal: J Virol Date: 2022-08-03 Impact factor: 6.549
Authors: Thomas J Gniadek; Joshua M Thiede; William E Matchett; Abigail R Gress; Kathryn A Pape; Jessica K Fiege; Marc K Jenkins; Vineet D Menachery; Ryan A Langlois; Tyler D Bold Journal: Transfusion Date: 2020-10-02 Impact factor: 3.157
Authors: Andrea Trevisan; João M G Candeias; Patrícia Thomann; Luisa L Villa; Eduardo L Franco; Helen Trottier Journal: J Med Microbiol Date: 2020-07 Impact factor: 2.472
Authors: Monica Zahreddine; Marie-Hélène Mayrand; Christian Therrien; Andrea Trevisan; Carole Dagenais; Patricia Monnier; Louise Laporte; Joseph Niyibizi; Catherine Deshaies; Ana Maria Carceller; William Fraser; Paul Brassard; Jacques Lacroix; Marie-Josée Bédard; Isabelle Girard; François Audibert; François Coutlée; Helen Trottier Journal: EClinicalMedicine Date: 2020-04-07